ESMO Virtual 2020: Cabozantinib plus atezolizumab in non-clear cell kidney cancer

Non-clear cell renal cell carcinoma (RCC) accounts for about 25% of all RCC diagnoses and usually has worse outcomes than clear cell RCC. Both cabozantinib and immune checkpoint inhibitors have shown preliminary activity in non-clear cell RCC. Cabozantinib appears to enhance the response to immune checkpoint inhibitors and has shown encouraging results in combination with […]

read more

ESMO Virtual 2020: Nivolumab plus cabozantinib for first-line advanced kidney cancer

At the European Society of Medical Oncology (ESMO) Virtual Congress 2020, Dr Choueiri from Dana Farber Cancer Institute in Boston, USA presented the results of the phase 3 CheckMate-9ER trial evaluating the combination of nivolumab and cabozantinib compared to sunitinib in the first-line treatment of patients with advanced or metastatic renal cell carcinoma (RCC). Each […]

read more

ESMO Virtual 2020: Four-year follow-up data from nivolimuab plus ipilimumab in metastatic kidney cancer

Over the past 2 years, the use of combination therapies for the first-line treatment of metastatic renal cell carcinoma (RCC) has become the standard of care for these patients. The first combination was nivolumab plus ipilimumab, which demonstrated a survival benefit over sunitinib in patients with intermediate and poor risk metastatic RCC (CheckMate-214). Shortly after, […]

read more

New targeted therapy shows potential for previously treated metastatic kidney cancer

A phase II study published in Frontiers in Oncology last month investigated the potential of a new targeted therapy called anlotinib for the treatment of people with metastatic renal cell carcinoma (RCC) that had already been treated with a VEGF tyrosine kinase inhibitor (TKI). Forty-two (42) patients were included in the study. The cancer progressed […]

read more

ASCO 2020: Implications of the research presented at ASCO 2020 on the treatment of advanced kidney cancer

In this video presentation, Dr Toni Chouieri discusses the SAVOIR, COSMIC-313, and OMNIVORE kidney cancer studies, all of which were presented at the American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Programme. COSMIC-313 is a phase III study of cabozantinib in combination with nivolumab and ipilimumab in patients with untreated advanced renal cell carcinoma […]

read more

The effect of age and gender on outcomes in kidney cancer

In this interview, Dr Rana McKay discusses the impact of age and gender on the outcomes of patients with renal cell carcinoma (RCC) who are receiving targeted treatment options and the implications of these findings for individualised care. She also touches upon the influence of age and gender on the toxicity of systemic treatments and […]

read more

Combination immunotherapy plus VEGFR inhibitor for favourable risk and elderly kidney cancer patients

A study published in Clinical Genitourinary Cancer this month looks at treating patients with favourable risk metastatic renal cell carcinoma (RCC) and elderly patients with a combination of immune checkpoint inhibitors and vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKIs). Immune checkpoint inhibitors and VEGFR inhibitors are the most commonly used medications for […]

read more

COVID-19 outcomes in patient with cancer on anti-cancer treatments

Back in March at the start of the COVID-19 pandemic in the UK, people taking chemotherapy, immunotherapy or protein kinase inhibitors for treatment of their cancer were considered to be extremely vulnerable to coronavirus infection and were asked to shield for 12 weeks. At the time, since cancer and its treatments can lower your ability […]

read more

Bone metastases are associated with poor prognosis in papillary kidney cancer

A recent retrospective study looked at the data from 49 patients with metastatic papillary renal cell carcinoma (RCC) who were taking targeted therapy (VEGF-TKIs). The study showed that patients on targeted therapy and with bone metastases from papillary RCC have worse progression-free survival and overall survival than patients without bone metastasis. Patients with papillary RCC […]

read more

Atezolizumab alone or in combination with bevacizumab for untreated metastatic kidney cancer

This paper reports patient-reported outcomes from the phase 2 IMmotion150 study to assess the safety and efficacy of atezolizumab alone or in combination with bevacizumab versus sunitinib in 305 untreated metastatic renal cell carcinoma (RCC) patients. For all patients in the study, objective response rates were 25%, 32%, and 29% for atezolizumab alone, atezolizumab plus […]

read more
Showing 1 to 10 of 38 results
  TOP